exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087713 RNA Name: hsa-miR-1286 RNA Type: miRNA Chromosome: chr22 Starnd: - Coordinate: Start Site(bp): 20249145 End Site(bp): 20249165 External Links: hsa-miR-1286

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand TRIO chr5 14143342 14532128 + TXLNA chr1 32179675 32198285 + CSNK1E chr22 38290691 38318084 - NT5DC2 chr3 52524385 52535054 - ERLIN1 chr10 100150094 100186033 - BTG2 chr1 203305491 203309602 + GOLGA3 chr12 132768914 132829078 - ABCA2 chr9 137007234 137028922 - SSR2 chr1 156009048 156020951 - LUZP1 chr1 23084023 23177808 - RUBCN chr3 197668867 197749727 - CBX6 chr22 38861422 38872249 - KMT2A chr11 118436490 118526832 + LAMTOR1 chr11 72085895 72103297 - PHF12 chr17 28905250 28951771 - NPTX1 chr17 80466834 80477843 - ZXDB chrX 57591652 57597545 + PHLDA3 chr1 201464278 201469237 - NIPSNAP1 chr22 29554808 29581327 - IGDCC3 chr15 65327127 65378002 - TNRC6B chr22 40044817 40335808 + DNAJC30 chr7 73680918 73683453 - ALG10B chr12 38316762 38329721 + RBM4 chr11 66638617 66668374 + ABHD14B chr3 51968510 51983409 - ATXN2L chr16 28823035 28837237 + CPA4 chr7 130293134 130324180 + FGFR1 chr8 38400215 38468834 - HDGF chr1 156742109 156766925 - ATP8B2 chr1 154325553 154351304 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001588 chr6 26204839 26205043 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC010327.5 chr19 55216660 55221616 + AC016876.2 chr17 7581964 7584086 - AC124068.2 chr15 89335053 89336161 + DNAAF4-CCPG1 chr15 55355248 55498360 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.